16. Recarbrio


Active ingredient: imipenem, cilastatin, and relebactam
Disease: complicated UTIs and abdominal infections
Peak sales estimate: n/a
Approved: July 17, 2019
Company: Merck

The scoop: While many Big Pharma companies have exited antibiotic R&D work, Merck is pressing along and this summer won FDA approval for Recarbrio to treat complicated urinary tract infections and complicated intra-abdominal infections. While the drugmaker hasn’t scored major commercial success in the field since its $8.5 billion Cubist buyout, it’s not giving up on the challenge of antibiotic resistance. Recarbrio is indicated for use when patients don’t have other options, so that factor limits its market and sales potential. Recarbrio’s FDA nod followed a label expansion into certain types of pneumonia for Zerbaxa, an antibiotic picked up in the Cubist buyout. — Eric Sagonowsky

16. Recarbrio

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.